Ad-hoc | 7 November 2000 09:39

Ad hoc-Service: Rhein Biotech N.V. engl.

Ad hoc-Mitteilung verarbeitet und übermittelt durch die DGAP. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. —————————————————————————— Rhein Biotech Announces New Management Structure – Second management layer extended to include R&D Director, Director Product Development, Business Director Vaccines, Medical Director – Dr. Alexander Strasser appointed as Scientific Counsel – New appointments: Ivo Timmermanns formerly at BASF Pharma and Christian Loucq, formerly at SmithKline Beecham Maastricht, 7th November 2000 – As part of its strategic development the Rhein Biotech Group, which by means of acquisitions and alliances this year, has developed into a fully integrated biotech company, announces the extension of its management team Dr. Zbigniew A. Janowicz (49), formerly responsible for clinical development and registration will assume the position of R&D Director for the Rhein Biotech Group. As a leading scientist in Hansenula polymorpha research with a PhD in biochemistry, he was one of the founders of Rhein Biotech and later on worked for international companies in the field of tissue repair. Dr. Bernardus Rademaker (56), previously an external consultant will be Director Product Development for the Group. He holds a PhD in biology and worked for Solvay Duphar Weesp for four years. He has extensive experience in pharmacology and cancer research. Dr. Alexander Strasser (47) will step down as Chief Scientific Officer and take up the position of Scientific Counsel to advise the company on matters relating to gene expression, particularly in Hansenula Polymorpha yeast. Within the framework of the new organisation the position of Chief Scientific Officer will not be filled. Ivo Timmermanns (40), will be appointed as Medical Director. Timmermanns was responsible for the strategic development of special medicines and managed the co-ordination of clinical studies at BASF Pharma. Dr. Christian Loucq (49), who was Vaccines Director at Smithkline Beecham, will join Rhein Biotech as Business Director Vaccines and will be responsible for strategic extension of the vaccine business. With a background in medicine, epidemiology and public health, Dr Loucq has over twenty years experience in the vaccine market in Asia, Africa, and the Middle East. “This extension and the new management structure is a logical step in our strategic development. Through alliances and acquisitions Rhein Biotech has developed from being a technology provider to a fully integrated biotech company this year. This development is reflected in the new organisational structure. The fact that we can attract top-class managers from the pharma industry shows that Rhein Biotech is only at the beginning of its growth course” explains Frank Ubags, CFO of the Rhein Biotech Group. More information about Rhein Biotech is available on our website www.reinbiotech.com or from one of the following contacts: Valerie Ward, Investor Relations Rhein Biotech N.V., Maastricht (NL) T:+31 (0)43/3 5678 98 F: +31 (0)43/35678 99 e: investor@rheinbiotech.com I: www.rheinbiotech.com Stephanie Krone vom Hoff Kommunikation GmbH, Düsseldorf (D) T:+49 (0)211 / 515 805-16 F:+49 (0)211/ 515 805-55 c: s.krone@vomhoff.de Ende der Mitteilung